Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Prices Public Offering of Stock and Warrants, Expects $10M in Proceeds

NEW YORK (GenomeWeb) – Biocept late on Monday priced its public offering of 8 million shares of its common stock and warrants to purchase up to 8 million shares of its stock. 

The combined offering price is $1.25 per share, the company said, adding the warrants have a per share exercise price of $1.56. The warrants are exercisable immediately and will expire five years from the date of issuance. Biocept anticipates gross proceeds of approximately $10 million from the offering. 

The company has granted the offering's underwriters a 45-day overallotment option to purchase up to 1.2 million additional shares of common stock and/or 1.2 million additional warrants. Aegis Capital and Feltl are the joint book-running managers for the offering, which is expected to close on Feb. 13. 

In an amended prospectus last week, the San Diego-based firm said that it planned to offer up to $11.5 million in common stock and up to $11.5 million in common stock issuable upon the exercise of warrants.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.